BOB体育

Skip to main content
(352) 273-5550

Sub Subramony, MD : Research

Neuromuscular Medicine Specialist

Additional languages:
Hindi,
Malayalam,
Tamil
Photo of Sub Subramony
(352) 273-5550 MyUFHealth

Research at a glance

Top areas of exploration

  • Spinocerebellar Ataxias , 31 publications
  • Friedreich Ataxia , 29 publications
  • Phenotype , 19 publications
  • Spinocerebellar Degenerations , 17 publications

Research activity

178 publications

9,337 citations

Why is this important?

Focus

My key research interests include phenotypic characterization, phenotype-genotype correlations and pathogenic mechansims in genetically induced cerebellar ataxias and muscular dystrophies. In addition, I also am interested in developing assessment methods, biomarker discovery and therapeutic modalities for such diseases.

Active clinical trials

Vertex Drug

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Investigator
Sub Subramony
Status
Accepting Candidates
Ages
18 Years - 64 Years
Sexes
All
HARBOR

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Investigator
Sub Subramony
Status
Accepting Candidates
Ages
16 Years - 65 Years
Sexes
All
Frataxin

The purpose of this research study is to determine a way to measure frataxin messenger RNA (mRNA) in fluids such as blood and cerebrospinal fluid (CSF) from patients with Friedreich's ataxia (FRDA). The gene mutation in FRDA leads to low levels of鈥�

Investigator
Sub Subramony
Status
Accepting Candidates
Ages
18 Years - 65 Years
Sexes
All

My publications

178 publications

2024

Roussy-L茅vy Syndrome: Pes Cavus, Tendon Areflexia, Amyotrophy, Gait Ataxia, and Upper Limb Tremor in a Patient with CMT Neuropathy.

Tremor and other hyperkinetic movements (New York, N.Y.)

鈥�

2024

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.

The Lancet. Neurology

鈥�

2024

SARA captures disparate progression and responsiveness in spinocerebellar ataxias.

Journal of neurology

鈥�

2024

Sensitivity of Advanced Magnetic Resonance Imaging to Progression over Six鈥塎onths in Early Spinocerebellar Ataxia.

Movement disorders : official journal of the Movement Disorder Society

鈥�

2024

The Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar Ataxias.

Cerebellum (London, England)

鈥�